Assessment of two complementary influenza surveillance systems: sentinel primary care influenza-like illness versus severe hospitalized laboratory-confirmed influenza using the moving epidemic method

Núria Torner 1,2,3*, Luca Basile 1, Ana Martínez 1,2, Cristina Rius 2,4, Pere Godoy 1,2, Mireia Jané 1,2, Ángela Domínguez 2,3 and The Working Group on PIDIRAC Sentinel Surveillance of Catalonia

Abstract

Background: Monitoring seasonal influenza epidemics is the cornerstone to epidemiological surveillance of acute respiratory virus infections worldwide. This work aims to compare two sentinel surveillance systems within the Daily Acute Respiratory Infection Information System of Catalonia (PIDIRAC), the primary care ILI and Influenza confirmed samples from primary care (PIDIRAC-ILI and PIDIRAC-FLU) and the severe hospitalized laboratory confirmed influenza system (SHLCI), in regard to how they behave in the forecasting of epidemic onset and severity allowing for healthcare preparedness.

Methods: Epidemiological study carried out during seven influenza seasons (2010–2017) in Catalonia, with data from influenza sentinel surveillance of primary care physicians reporting ILI along with laboratory confirmation of influenza from systematic sampling of ILI cases and 12 hospitals that provided data on severe hospitalized cases with laboratory-confirmed influenza (SHLCI-FLU). Epidemic thresholds for ILI and SHLCI-FLU (overall) as well as influenza A (SHLCI-FLUA) and influenza B (SHLCI-FLUB) incidence rates were assessed by the Moving Epidemics Method.

Results: Epidemic thresholds for primary care sentinel surveillance influenza-like illness (PIDIRAC-ILI) incidence rates ranged from 83.65 to 503.92 per 100,000 h. Paired incidence rate curves for SHLCI–FLU / PIDIRAC-ILI and SHLCI–FLUA/ PIDIRAC-FLU showed best correlation index’ (0.805 and 0.724 respectively). Assessing delay in reaching epidemic level, PIDIRAC-ILI source forecasts an average of 1.6 weeks before the rest of sources paired. Differences are higher when SHLCI cases are paired to PIDIRAC-ILI and PIDIRAC-FLUB although statistical significance was observed only for SHLCI-FLU/PIDIRAC-ILI (p-value Wilcoxon test = 0.039).

Conclusions: The combined ILI and confirmed influenza from primary care along with the severe hospitalized laboratory confirmed influenza data from PIDIRAC sentinel surveillance system provides timely and accurate syndromic and virological surveillance of influenza from the community level to hospitalization of severe cases.

Keywords: Sentinel surveillance, Influenza, Epidemic, Threshold, Primary health care, Influenza like illness, Hospitalization
Background
Influenza seasonal epidemics occur yearly during each hemisphere's winter season, whether it be in the Northern or Southern hemisphere. Acute respiratory infection caused by influenza virus ranges from mild to severe and can even cause death in at risk population such as the elderly and young infants. Annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250,000 to 500,000 deaths worldwide. Hospitalization and death occur mainly among these high risk groups, which include also pregnant women and anyone with underlying medical conditions such as diabetes, obesity, cardiovascular or chronic obstructive pulmonary disease [1, 2].

Influenza epidemics can cause an overload in the healthcare system because of high incidence rates of affected population, especially during peak illness periods. Influenza surveillance is made up information on morbidity and mortality as well as virological assessment of circulating influenza viruses. The resulting assessment and interpretation of these data can support public health authorities to implement special measure to strengthen capacity and preparedness which will in turn translate into a reduction of morbidity and mortality. In most developed countries a network of sentinel physicians report cases attended for influenza-like illness (ILI), which is used as a proxy to estimate influenza virus circulation, and on the other hand collect samples for virological confirmation, identification of causative virus and describe predominant circulating type and subtype of influenza virus [3].

In some countries community-based ILI reporting systems and indicators such as school and workplace absenteeism data are recorded weekly and have been used to estimate a proxy influenza intensity in combination with routine outpatient physician consultations and hospital influenza sentinel surveillance data [4, 5].

Sentinel surveillance networks in primary care are a readily available and basic source of data that estimates disease burden of ILI cases as well as laboratory-confirmation of respiratory viruses, including influenza, by systematic sampling of ILI cases. From these data thresholds can be established to pinpoint the start and termination of influenza seasonal epidemics. Other relevant information gathered, such as patients’ vaccination status, will allow for vaccine effectiveness estimation [6]. Influenza causes high rates of consultations, hospitalization and, in severe cases, death every year and vaccination is the main preventive measure undertaken globally, but despite policy recommendations, influenza vaccination uptake remains suboptimal in most countries. Low levels of vaccination coverage among at high risk groups is a missed opportunity for preventing influenza infection and complications that can derive into hospitalization and severe outcome [6]. In addition, influenza vaccine manufacturing is conditioned to antigenic changes in the circulating strains detected by the surveillance systems and when these changes occur with respect to onset of seasonal epidemics. Furthermore, immune response varies depending on age, underlying diseases, and immunosuppression [7].

In all, vaccine effectiveness is hampered and derives into low vaccine uptake. These facts underscore the importance of any surveillance data available whatsoever, making them essential for the detection and preparedness for any changes or unusual behavior of seasonal and non-seasonal influenza. However, a limitation to sentinel surveillance is the limited coverage of population within a geographical area and the bias towards young children who are more prone to seek medical assistance. During the 2009 influenza pandemic, the need to assess influenza severity became evident and from then on a number of European such as Spain, as well as other, countries introduced surveillance of severe disease and death due to influenza into their seasonal influenza surveillance systems [8–10].

In Catalonia severe hospitalized confirmed influenza data from sentinel hospitals are informed on a weekly basis to the Daily Acute Respiratory Infection Sentinel Surveillance System of Catalonia (PIDIRAC) [9]. Identification of admissions due to pneumonia, to intensive care units and deaths among hospitalized laboratory confirmed influenza cases is available and information on hospitalization, clinical presentation, underlying diseases, vaccination and antiviral treatment as well as and mortality is added to notification records for influenza cases.

Hospital admissions for influenza and pneumonia through emergency departments provide some information on community cases, yet it is currently not easy to track a patient's journey from community care (primary care consultations) into the hospital and the lack of denominator (source population) data is a major limitation of hospital-based surveillance [8].

In October 2010, the Public Health Agency of Catalonia of the Department of Health in Catalonia, a region in the northeast of Spain with 7.5 million inhabitants, implemented the surveillance of severe hospitalized cases of confirmed influenza as a tool to complement information provided by the influenza sentinel system based on primary healthcare physicians implemented since 1998 [9]. The aim of this study is to assess and compare which of the two networks, primary care and hospital based severe cases, grants a more timely description of influenza epidemics.

Methods
Data sources
The PIDIRAC primary care network was composed by 60 sentinel physicians, general practitioners and pediatricians, covering 1% of the total population of Catalonia. Representativeness in terms of age, sex, and urban or
rural setting was considered. Sentinel physicians reported ILI cases detected in their reference populations on a daily basis, following the European ILI case definition [9, 11]. For virological influenza surveillance, systematic swab sampling (nasal or oropharyngeal) of the first 2 ILI patients each week which are sent to the network-affiliated laboratory (Hospital Clinic, Barcelona) for detection of a batch of respiratory viruses, including influenza. Samples are confirmed by polymerase chain reaction (PCR) and/or culture of nasopharyngeal swabs. Respiratory tract samples were processed within 24 h of receipt at the laboratory. Subsequently, two specific one-step multiplex real-time PCR was carried out for typing A/B influenza virus and subtyping influenza A virus [12].

The information collected in the PIDIRAC includes data on demographic, clinical and virological characteristics, seasonal vaccination status, chronic conditions, and pregnancy. Indicators provided by the PIDIRAC sentinel system for seven influenza seasons (2010–2011 to 2016–2017) was analyzed in the study. Indicators for this data source were the incidence rate of ILI syndromes (PIDIRAC-ILI) calculated according to weekly population under surveillance by each sentinel physician of the network that is reporting. Laboratory influenza confirmed isolates from reported ILI cases from primary care (PIDIRAC-FLU) were registered as weekly incidence rate positive to influenza. The latter indicator was separated as to influenza virus type A (PIDIRAC-FLUA) and type B (PIDIRAC-FLUB).

The surveillance of Severe Hospitalized Laboratory Confirmed Influenza (SHLCI) was made up by twelve tertiary care hospitals representing a mean of 63.6% of the population under surveillance. Coverage increased from 53.3 to 94% of the total Catalan population in the 2015–2016 season. The catchment population for SHLCI surveillance was the population assigned to each hospital by the health system as a referral facility for any condition leading to hospitalization.

The system is based on the notification of those laboratory confirmed influenza hospitalized cases admitted to the sentinel facility and who met the SHLCI case definition: Any case with clinical features compatible with influenza (sudden onset of symptoms and at least one of the following four systemic symptoms: fever or feverishness, malaise, headache, myalgia and at least one of the following three respiratory symptoms: cough, sore throat, shortness of breath) [11], requiring hospitalization for clinical severity (at least one of the following criteria: pneumonia, septic shock, acute respiratory distress syndrome, multiple organ dysfunction syndrome, or admission to intensive care unit (ICU)) [9].

Only cases that were laboratory confirmed for influenza and met the SHLCI case definition were reported, regardless of whether they had been previously admitted to emergency room and transferred to ward or admitted to ward on initial consultation.

Date of hospitalization and type and subtype of influenza virus were collected, other clinical and sociodemographic variables and outcomes, although collected, were not relevant for this study. We used data obtained from the surveillance of SHLCI for the same study period as in primary care surveillance for ILI, to calculate the cumulative hospitalization rates for each season and threshold for epidemic onset. Indicators for this data source were the incidence rate of severe hospitalized influenza laboratory confirmed cases (SHLCI-FLU) and separated as to influenza virus type A (SHLCI-FLUA) and type B (SHLCI-FLUB). For SHLCI-FLU and SHLCI-FLUA and FLUB the same method was applied to calculate epidemic thresholds using MEM system [13, 14].

Statistical analysis
Epidemic thresholds for incidence rates by the Mobile Epidemics Method (MEM) were calculated and categorized as to intensity of epidemic (baseline, low, moderate, high and very high) for the PIDIRAC-ILI and PIDIRAC-FLU indicators taking into account the seven epidemic seasons included in the study [14, 15].

Epidemic curves obtained from both data sources were paired as PIDIRAC-ILI vs SHLCI-FLU, PIDIRAC-FLU vs SHLCI-FLU, PIDIRAC-FLUA vs SHLCI-FLUA and PIDIRAC-FLUB vs SHLCI-FLUB. For each pair, normal partial correlation were calculated at log scale. The week at which incidence rate exceeds estimated epidemic threshold level was used as an indicator to identify whether one source forecasts the onset of the epidemic activity with respect to the other. To calculate this factor by pairs the Wilcoxon signed rank test was carried out.

To compare intensity of influenza epidemic observed by both data sources, correlation of intensity was calculated for each pair and the percentage of agreement within each epidemic threshold level. Correlation was defined as the proportion of weeks in which the observed intensity of activity for one source matches with the observed by the other source. To identify whether one source forecasts the onset of the epidemic with respect to the other for each season and for each indicator, the week at which incidence rate exceeds the estimated epidemic threshold level, this factor was studied by pairs according to Wilcoxon signed rank test.

The analysis was performed using the SPSS v.18 statistical package and the R v3.3.0 statistical software (http://cran.r-project.org).

Results
Estimated epidemic threshold levels obtained by the MEM method for each source of data are presented in Table 1. Of the seven seasons under study, there was co-circulation of
influenza virus type A and B in 3 of seasons (2010–2011, 2014–2015 y 2015–2016), in the 2011–2012 season influenza virus A was predominant and some sporadic circulation of influenza type B virus, in the 2012–2013 season there was predominant circulation of virus B with sporadic cases of A, and in seasons 2013–2014 and 2016–2017 there was absolute predominance of influenza A virus (Fig. 1).

Epidemic intensity reached moderate threshold levels for ILI incidence rates and influenza virus isolate incidence in all epidemic seasons except for the 2010–2011 post-pandemic season, when the duration of the epidemic was longer in time but of lower intensity. Highest peak incidence levels were reached in 4 seasons from 2011 to 2015. In seasons with co-circulation of both A and B influenza virus, individually assessed intensity did not exceed moderate level (Fig. 2). Influenza A epidemic curves presented higher peaks of epidemic intensity than B influenza virus but with shorter duration.

Assessment of the SHLCI source showed an increase in the rate of cases for the four last seasons (2013–2017)
although threshold level reached did not surpass the moderate level and did not reach high intensity level.

Incidence rates of SHLCI-FLUA cases reached peak values of 15–20 cases/100,000 inhabitants, which are set within the moderate intensity level during epidemic weeks, while incidence rates of SHLCI-FLUB were less frequent and displayed lower incidence rates of 3–5 cases/100,000 inhabitants (Fig. 3), slightly exceeding baseline threshold level in those seasons with greater B type virus circulation.

When comparing PIDIRAC–FLU and SHLCI, a decreasing severity trend was observed for the first three seasons, while for the latter four seasons the trend was opposite showing a constant increase in SHLCI incidence with respect to PIDIRAC–FLU (Fig. 4). SHLCI-FLUB cases in seasons 2014/2015 and 2015/2016 showed a marked increase with respect to PIDIRAC-FLUB. Paired incidence curves for SHLCI -FLU and PIDIRAC-ILI and SHLCI -FLUA and PIDIRAC-FLUA showed the best correlation index (0.805 and 0.724 respectively).

Comparison of the curves according to MEM intensity levels, paired curves that showed higher correspondence in their levels of intensity was the SHLCI -FLUB/PIDIRAC-FLUB pair, being above 85% globally and 55% during epidemic weeks (Table 2). Assessing delay in reaching epidemic level, the PIDIRAC-ILI source forecasts an average of 1.6 weeks before SHLCI. Differences are higher when SHLCI cases are paired to PIDIRAC-ILI and PIDIRAC-FLUB (SHLCI-FLU/PIDIRAC-ILI and SHLCI-FLUB/PIDIRAC-FLUB), although statistical significance was observed only for SHLCI-FLU/PIDIRAC-ILI ($p$-value Wilcoxon test $= 0.039) (Table 2).

**Discussion**

This study is based on surveillance data of ILI incidence rates from primary care sentinel surveillance, virology
results from sampling by sentinel primary care physicians and severe laboratory-confirmed influenza (SHLCI) that required hospital admission during seven influenza epidemic seasons, from 2010 to 2017, in Catalonia. Data obtained from these seven epidemic seasons showed a good correlation between the two systems, primary care and SHLCI, although some differences in prompt detection of epidemic onset were observed according to predominant circulating influenza virus.

Case definitions with a lower relative specificity for influenza, such as ILI can decrease the specificity of the model to detect an influenza season [16]. This occurs because of the increasing circulation of other respiratory pathogens, such as respiratory syncytial virus that add up to ILI Incidence rates in the primary care system, yet this is not so in the SHLCI because these are all laboratory confirmed influenza cases [16, 17]. Other factors influencing outpatient consultation rates, such as public concern, or the circulation of a novel recombinant influenza virus with pandemic potential, can also act as amplifiers of ILI consultation rates and disease burden results [18]. This may result in patterns with bimodal waves as observed in some seasons such as the 2014–2015 or pre-epidemic peaks as observed in the 2010–2011 season. Nevertheless increase in ILI rates was consistent with increases in influenza laboratory confirmation of primary care sentinel samples as well as severe confirmed influenza hospitalization rates, a fact that has also been observed by other researchers as well [19]. The complementary virological data available in the SHLCI should be more accurate to confirm the start of the epidemic period. In the present study this fact was observed only when there is Influenza B predominant circulation. Although the low incidence of influenza B virus in the seasons studied does not allow to conclude about the benefit of combining the two systems of surveillance respect the surveillance made by PDIRAC outpatient sentinel System. This fact differs from the observations from Murray et al. that found timing to be the same in all influenza seasons where influenza A (H3N2) was the most prevalent subtype and that using historical data from all influenza seasons regardless of circulating subtype, weeks predicted to be above the epidemic threshold do not change. Meaning that the MEM approach could be useful for planning regardless influenza virus subtype [19].

The present study is an observational study with strengths and limitations. As a strength we can highlight that there are few studies investigating timeliness of sentinel primary care vs SHLCI to predict the onset of the
epidemic allowing for on time preparedness to cope with the influenza epidemic and will allow for timely assessment of intensity and severity of an influenza epidemic.

This study reveals the importance of both systems to understand yearly influenza epidemic behavior and to strengthen healthcare resource preparedness.

Although MEM was primarily developed for modeling ILI data, it has been proven successful with SHLCI data showing that influenza severe cases’ waves correlate well with ILI, with higher epidemic thresholds and shorter range among intensity thresholds. Intensity, understood as the level of the population consultation rates or the percentage of ILI primary care consultations which is not synonymous of intensity or severity specific to influenza, but has proven to be one of the most reliable indicators to describe the impact of influenza on the population. On the other hand, SHLCI can complement primary care indicators giving a picture of the severity of the epidemic. Comparing intensities and severity across seasons is essential for the understanding of seasonal epidemic patterns and of future pandemics, and to assess control measures, such as the effectiveness of vaccination campaigns [20].

As a limitation we consider the fact that a certain proportion of the population will not seek medical attention. Other complementary systems could possibly account for those who do not seek health care attention for ILI have been described such as Influweb or internet flu consultation trends such as Google flu trends, although these systems have, by themselves alone, low representability [3, 21].

An epidemic threshold was determined for the ILI consultation rates reported by the sentinel physicians and for the SHLCI to assess the period of increased influenza epidemic earlier. Yet on time complete reporting of hospitalized severe cases is, at the best scenario, on a week’s delay, making this system unable to predict an overload in hospital resource demand with anticipation. Nevertheless the surveillance of SHLCI has the potential to reveal timely insights into epidemic severity as has been also pointed out by other authors [22–24].
Besides, the voluntary participation of hospitals that could account for a selection bias. However, although a selection bias cannot be ruled out, the 12 participating tertiary hospitals cover 62% of the population of Catalonia meaning that the effect can be assumed not to invalidate data.

Another limitation is the representativeness of the samples tested in primary care by the systematic sampling of two first weekly ILI patients attended. Other circulating respiratory virus can mimic influenza and contribute to increase in ILI incidence rates, not so in SHLCI that are all influenza confirmed. Thus, increase in hospitalization of SHLCI reflects true influenza virus circulation, albeit a certain delay depending on circulating virus predominance. The implementation of a third hospital warning system based on data from emergency department records for laboratory confirmed influenza would be desirable to further improve timely information to healthcare for appropriate response.

Another limitation to determining burden of hospitalization due to confirmed influenza is presented by the lack of the inclusion in the sentinel surveillance system of a data source for influenza hospitalization. The use of other data systems such as hospital discharge data might spare the underestimation of the burden of laboratory confirmed influenza hospitalization [25]. Improvement to upgrade the assessment of influenza burden could be achieved by adding an automated surveillance system based on ICD-10 codes assigned by physicians after emergency room consultation [26].

### Conclusions

Results of two different surveillance systems during seven influenza seasons studied showed similar trends and were highly correlated with each other. The ILI consultation rates reported by the sentinel primary care physicians remain the basis of surveillance in Catalonia, because the system integrates epidemiological and virological information. Hospital data and virological data will remain very important to provide information on the severity, molecular and phenotypic characterization of the viruses, and whether the ILI incidence is truly related to influenza virus infections.

The combined PIDIRAC Influenza sentinel surveillance system provides timely and accurate syndromic and virological surveillance of influenza from the community level to hospitalization of severe cases. The implementation of a hospital warning system based on data from emergency department records would be desirable as a complementary component of the combined outpatient-SHLCI scheme, allowing to inform control measures to lessen the burden of influenza in Catalonia and ensure access to quality timely information to health care for accurate preparedness.

### Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| CI           | Confidence interval; FLU: Laboratory confirmed influenza; FLU-A: Laboratory confirmed influenza A virus; FLU-B: Laboratory confirmed influenza B virus; ILI: Influenza like illness; MEM: Moving Epidemics Method; PIDIRAC: Daily Acute Respiratory Infection Sentinel Surveillance System of Catalonia; SHLCI: Severe Hospitalized Laboratory Confirmed Influenza |

### Acknowledgements

The authors also wish to acknowledge the support from all colleagues that make up the PIDIRAC Working Group on Sentinel Primary care and Severe Hospitalized Laboratory Confirmed Influenza in Catalonia: Aizpurua J, Alonso J, Azemar J, Alzpurua P, Ardaya PM, Basas MD, Batalla J, Biendicho P, Bonet M, Callado M, Campos S, Casanovas JM, Ciurana E, Clapes M, Cots JM, De la Rica D, Domingo I, Elizalde G, Escapa P, Fajardo S, Fau E, Fernandez O, Fernandez M, Ferrer C, Forcada A, Fos E, Gadea G, Garcia J,

### Table 2

Delay in achieving epidemic threshold and correlation between curves and MEM epidemic levels

| Influenza season | SHLCI / PIDIRAC-ILI | SHLCI / PIDIRAC-FLU | SHLCI-FLUA / PIDIRAC-FLUA | SHLCI-FLUB / PIDIRAC-FLUB |
|------------------|---------------------|---------------------|---------------------------|---------------------------|
| 2010_11          | 1                   | 1                   | 1                         | na                        |
| 2011_12          | 2                   | 2                   | 2                         | na                        |
| 2012_13          | 6                   | 3                   | na                        | 3                         |
| 2013_14          | 1                   | 1                   | 1                         | na                        |
| 2014_15          | 1                   | 2                   | 2                         | 1                         |
| 2015_16          | 0                   | -1                  | -1                        | 4                         |
| 2016_17          | 0                   | 0                   | 0                         | na                        |

mean ± SD 1.6 ± 2.1 1.1 ± 1.3 0.8 ± 1.2 2.7 ± 1.5

P-value 0.039 0.071 0.129 0.109

Correlation (LN) 0.805 (0.814) 0.694 (0.749) 0.724 (0.743) 0.583 (0.666)

MEM correlation 0.745 0.649 0.752 0.689

Global ILSR 81.0% 77.5% 80.8% 85.9%

Epidemic ILSR 47.4% 38.2% 46.0% 58.8%

No not available, LN natural logarithm, ILSR Influenza Likelihood Signed Rank, MEM Moving Epidemics Method, SHLCI Severe hospitalized laboratory confirmed influenza, SHLCI-FLUA A Severe hospitalized laboratory confirmed influenza type A, SHLCI-FLUB Severe hospitalized laboratory confirmed influenza type B, PIDIRAC-ILI Incidence rate for Primary care Influenza like illness, PIDIRAC-FLU Incidence rate for Primary care influenza laboratory confirmed cases, PIDIRAC-FLUA Incidence rate for Primary care influenza type A laboratory confirmed cases, PIDIRAC-FLUB Incidence rate for Primary care influenza type B laboratory confirmed cases
Garcia R, Gattis C, Gelado MJ, Grau M, Grivé M, Guzman MC, Hernández R, Jimenez G, Juscafeña A, Lluasa AM, López C, Kristensen L, Maciá E, Mainou A, Marco E, Martínez M, Martínez JG, Manarola K V, Masa R, Moncosí X, Naranjo MA, Navarro D, Ortolá E, París F, Pérez MM, Pozo C, Pujol R, Ribatallada A, Ruiz G, Sabaté S, Sanchez R, Sarrià N, Tanagó E, Teixidó AM, Torres A, Valén E, Van Esso D, Van Tarjwick C, Vink Schoenholzer R, Zábalta E, Marcolos MA, Mosquera MDM, de Molina F, Rubio E, Isanta R, Anton A, Pumarola T, Villa A, Gorriño P, Espose M, Andrés, Barcenailla F, Navarro G, Barrebei I, Pou J, Alvarez P, Plasencia E, Rebull J, Sala MR, Riera M, Camps N, Follia N, Oller A, Godoy P, Bach P, Ruus C, Hernández R, Perez R, Torra C, Carol M, Minguez S, Marce R, García-Pardo G, Giona M, Alvarez A, Ramon JM, Módol JM, G Mena, Campins M, Massuet C. Tora G, Ferràs J, Ferrús G.

Authors' contributions
All authors were involved at the initial start of the study. NT and LB conceived the idea of the study, conducted data analyses and prepared the manuscript. AM, MJ, PG, CR, and AD advised on data analyses and contributed to subsequent revisions of the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by the Program of Surveillance, Prevention and Control of Transmissible Diseases (PRVCET) of CIBER de Epidemiología y Salud Pública. (CIBERESP), Instituto de Salud Carlos III, Madrid and the Catalan Agency for the Management of Grants for University Research (AGAUR Grant Number 2017/SGR. 1342) the funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Availability of data and materials
Data is available upon request by the corresponding author of the manuscript.

Ethics approval and consent to participate
The study does not need formal ethical approval according to national guidelines with respect to public health surveillance activities according to the actual legislation on Public Health activities (Public Health Law 18/2009, October 22; Diari official DOGC 30/10/2009,Núm. S495 Available at: https://portaljudic.gencat.ca/ca/pjur_ocults/pjur_resultats_fitxa/?documentId=532 871&action=fitxa). All data are anonymous and derive from sentinel surveillance. Verbal participation consent in the surveillance system was obtained by each attending clinician as set in practice by patients’ rights legislation (Law 41/2002, Nov 14 (art 8, 9 i 10 Chapter IV).

No sensitive information was used and data were anonymized.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Health, Public Health Agency of Catalonia, Generalitat of Catalonia, Salavny Building, Roc Boronat 81-95, 08025 Barcelona, Catalonia, Spain. 2CIBER Epidemiología y Salud Pública (CIBERESP) Institute Carlos III, Madrid, Spain. 3Medicine Department, University of Barcelona, Barcelona, Spain. 4Public Health Agency of Barcelona, Barcelona, Spain.

Received: 2 November 2018 Accepted: 31 July 2019
Published online: 13 August 2019

References
1. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:10127.
2. Thompson WW, Weintraub E, Dhanak M, Cheng P-Y, Brammer L, Meltzer M, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses. 2009;3(1):37–49 (cited 2018 Dec 28). Available from: http://www.ncbi.nlm.nih.gov/pmc/uni:1944350.
3. Perrotta D, Bella A, Rizo C, Paolotti D. Participatory Online Surveillance as a Supplementary Tool to Sentinel Doctors for Influenza-Like Illness Surveillance in Italy. PLoS One. 2017;12(10):e0169801 (cited 2017 Jul 7). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226807/.
4. Dalton CB, Carlson SJ, Butler MT, Feisa J, Elvidge E, Dunehm D. FluTracking weekly online community survey of influenza-like illness annual report, 2010. Commun Dis Intell Q Rep. 2011;35(4):288–93.
5. Paterson B, Caddis R, Dunehm D. Use of workplace absenteeism surveillance data for outbreak detection [letter]. Emerg Infect Dis. 2011;17(10):1963–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106699/.
6. Jorgensen P, Mereckiene J, Cotter S, Johansen K, Tislova S, Brown C. How close are countries of the WHO European region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. Vaccine. 2016;34(46):5442–52 (cited 2018 Jun 27). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776404/.
7. Atsmon J, Caraco Y, Ziv-Seefer S, Shaivek D, Abramov E, Volokhov I, et al. Priming by a novel universal influenza virus (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine. 2014, 32(44):5816–23 Available from: https://doi.org/10.1016/j.vaccine.2014.08.031.
8. European Centre for Disease Prevention and Control. Severe influenza surveillance in Europe. Stockholm; 2012. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/20120614_SEUR_severe_influenza.pdf.
9. Department of Health PHA of. Pla d’informació de les infeccions respiratories agudes a Catalunya ( PIDIRAC ) 2017–2018 Estrategia de Vigilancia dels casos greus produïts per la infecció pel virus de la grip [Internet]. Barcelona; 2017. Available from: http://canalsalut.gencat.cat/ca/professionals/vigilancia-epidemiologica/pla-dinformatcio-de-les-infeccions-respiratories-agudes-a-catalunya-pidirac/. Accessed 15 Sept 2018.
10. Sullivan SG, Franklin LJ, Raupach J, Pennington K, Barea C, De Kuyver R. A brief overview of influenza surveillance systems in Australia, 2015. Commun Dis Intell Q Rep. 2016;40(3):E351–E355.
11. European Commission. Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions. 2018;2018:1(1):1–4. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:20180945&from=en.
12. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917–30. Available from: www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)60519-9/fulltext.
13. Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. BMC Infect Dis. 2013;13:541 Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848794/pdf/1471-2334-13-441.pdf.
14. Vega T, Lozano JE, Meerhoff T, Snacken R, Beauût J, Jorgensen P, et al. Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method. Influenza Other Respir Viruses. 2015;9(5):234–46.
15. Vega T, Lozano JE, Meerhoff T, Snacken R, Mott J, Ortiz de Lejarazu R, et al. Influenza surveillance in Europe: establishing epidemic thresholds by the Moving Epidemic Method. Influenza Other Respir Viruses. 2013;7(6):546–58 (cited 2018 Jun 27). Available from: http://doi.wiley.com/10.1111/j.1750-2659.2012.00422.x.
16. Green HK, Charlett A, Morán- productId 17411111. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226807/.
17. Opatowski L, Baguelin M, Eggro RM. Influenza interaction with cocirculating pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role for mathematical modelling. PloS Pathog. 2018;14(2): e1006779 [cited 2017 Aug 21]. Available from: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1006779.
18. Zheng X, Song Z, Li Y, Zhang J, Wang X-L. Possible interference between seasonal epidemics of influenza and other respiratory viruses in Hong Kong, 2014–2017. BMC Infect Dis. 2017;17(1):722 (cited 2018 Aug 21). Available from: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2888-5.
19. Murray JIK, Marques DFP, Cameron RL, Potts A, Bishop J, von Wissmann B, et al. Moving epidemic method (MEM) applied to virology data as a novel
real time tool to predict peak in seasonal influenza healthcare utilisation. The Scottish experience of the 2017/18 season to date. Euro Surveill. 2018; 23(11). https://doi.org/10.2807/1560-7917.ES.2018.23.11.18-00079.

20. Rakocevic B, Grgurevic A, Trajkovic G, Mugosa B, Sipetic Grujic S, Medenica S, et al. Influenza surveillance: determining the epidemic threshold for influenza by using the moving epidemic method influenza seasons. Eurosurveillance. 2019;24(12). Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.12.1800042.

21. Thursky K, Cordova SP, Smith D, Kelly H. Working towards a simple case definition for influenza surveillance. J Clin Virol. 2003;27(2):170–9.

22. Petel C, Lasserre A, Xavier A, Turbelin C, Blanchon T, Hanalik T. Hospitalization of influenza-like illness patients recommended by general practitioners in France between 1997 and 2010. Influenza Other Respi Viruses. 2013;7(1):74–84 [cited 2017 Jul 7]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780733/.

23. Chaves SS, Lynfield R, Lindegren ML, Bresee J, Finelli L. The US influenza hospitalization surveillance network. Emerg Infect Dis. 2015;21(9):1543–50.

24. Ayscue P, Murray E, Lyekyll T, Zipprich J, Harriman K, Salibay C, et al. Influenza-associated intensive-care unit admissions and deaths - California, September 29, 2013-January 18, 2014. MMWR Morb Mortal Wkly Rep. 2014; 63(7):143–7 [cited 2017 Jul 7]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24553197.

25. Williamson DA, Huang QS, Roberts SA, Grant CC, McArthur C, Baker MG. Surveillance for influenza using hospital discharge data may underestimate the burden of influenza-related hospitalization. Infect Control Hosp Epidemiol. 2012;33(10):1064–6 [cited 2017 Jul 7]. Available from: https://www.cambridge.org/core/product/identifier/S019594170003188X/type/journal_article.

26. Gerbier-Colomban S, Potinet-Pagliaroli V, Metzger M-H. Can epidemic detection systems at the hospital level complement regional surveillance networks: case study with the influenza epidemic? BMC Infect Dis. 2014; 14(1):381 Available from: http://biomedcentral.com/1471-2334/14/381.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.